ArticleRheumatology (Oxford, England)2026
Lifetime risk of malignancy in polymyalgia rheumatica: a population-based matched cohort study from southern Norway.
Article in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesPrior studies examining the malignancy risk in polymyalgia rheumatica (PMR) have reported conflicting results, with some indicating an increased risk within 6-12 months after diagnosis. This study assessed malignancy risk over the lifetime and at different follow-up horizons in a population-based inception cohort of PMR patients.
methodsAll incident PMR cases (n = 296) in Aust-Agder County, Norway, between 1987 and 1997 were enrolled at diagnosis in a prospective, population-based study. Diagnosis was ascertained clinically by rheumatologists, with all cases fulfilling Bird's criteria. Each PMR case was matched by age, sex and residency to 15 random comparators (n = 4440). Cancer incidence data were obtained from the Cancer Registry of Norway. Participants were followed until first cancer diagnosis, death or 31 December 2024. Malignancy risk was estimated using Cox regression stratified on matched groups.
resultsThe mean age at PMR diagnosis was 72 years, 67.6% were female and 95.6% were deceased by 31 December 2024. Median follow-up was 14.1 years in PMR patients and 13.9 years among comparators. Following the index date, 70 PMR patients (23.6%) and 1104 comparators (24.9%) developed malignancy. PMR was not associated with an increased malignancy risk (hazard ratio 0.94; 95% CI: 0.73, 1.21), nor with significant excess risk in separate analyses by cancer type or by time since diagnosis.
conclusionIn this long-term follow-up of a population-based PMR inception cohort, we found no excess malignancy risk at any time from PMR diagnosis through the end of life. These findings reinforce the notion that PMR is not a cancer-associated disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.